1-7 of 7
Shaji K. Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025

Peter M. Voorhees, Andrzej J. Jakubowiak, Shaji K. Kumar, Bindu Kanapuru, Andrea C. Baines, Vishal Bhatnagar, Rachel Ershler, Marc R. Theoret, Nicole J. Gormley, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 23–26.
https://doi.org/10.1158/1078-0432.CCR-21-1069
Published: 05 January 2022
View article titled, Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025
Open the PDF for Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025 in another window
Journal Articles

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Kenneth C. Anderson, Daniel Auclair, Stacey J. Adam, Amit Agarwal, Melissa Anderson, Hervé Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E. Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M. Ghobrial, Nicole J. Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J. Kelloff, Ilan R. Kirsch, Brandon Kremer, Ola Landgren, Elizabeth Lightbody, Oliver C. Lomas, Sagar Lonial, María-Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C. Munshi, Elizabeth K. O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J. Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A. Ross, Caroline C. Sigman, Katie L. Thoren, Suzanne Trudel, Gary Ulaner, Nancy Valente, Brendan M. Weiss, Elena Zamagni, Shaji K. Kumar
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5195–5212.
https://doi.org/10.1158/1078-0432.CCR-21-1059
Published: 01 October 2021
View article titled, Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Open the PDF for Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration in another window
Journal Articles

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma

Neeraj Sharma, James B. Smadbeck, Nadine Abdallah, Cinthya Zepeda-Mendoza, Moritz Binder, Kathryn E. Pearce, Yan W. Asmann, Jess F. Peterson, Rhett P. Ketterling, Patricia T. Greipp, P. Leif Bergsagel, S. Vincent Rajkumar, Shaji K. Kumar, Linda B. Baughn
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5430–5439.
https://doi.org/10.1158/1078-0432.CCR-21-0005
Published: 01 October 2021
View article titled, The Prognostic Role of <em>MYC</em> Structural Variants Identified by NGS and FISH in Multiple Myeloma
Open the PDF for The Prognostic Role of <em>MYC</em> Structural Variants Identified by NGS and FISH in Multiple Myeloma in another window
Journal Articles

Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma

Nadine Abdallah, Linda B. Baughn, S. Vincent Rajkumar, Prashant Kapoor, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Ronald S. Go, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Yi Lin, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Mustaqeem Siddiqui, John Lust, Robert A. Kyle, Rhett Ketterling, Leif Bergsagel, Patricia Greipp, Shaji K. Kumar
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6581–6588.
https://doi.org/10.1158/1078-0432.CCR-20-2283
Published: 15 December 2020
View article titled, Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
Open the PDF for Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma in another window
Journal Articles

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau, Ann T. Farrell, Nicole J. Gormley, Shaji K. Kumar, Ola Landgren, Nikhil C. Munshi, Michele Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven I. Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James L. Omel, Trevor J. Pugh, Gregory H. Reaman, Michael D. Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 3980–3993.
https://doi.org/10.1158/1078-0432.CCR-16-2895
Published: 01 August 2017
View article titled, The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Open the PDF for The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications in another window
Includes: Supplementary data
Journal Articles

Immune Therapies in Multiple Myeloma

Shaji K. Kumar, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5453–5460.
https://doi.org/10.1158/1078-0432.CCR-16-0868
Published: 14 November 2016
View article titled, Immune Therapies in Multiple Myeloma
Open the PDF for Immune Therapies in Multiple Myeloma in another window
Journal Articles

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Evanthia Galanis, S. Keith Anderson, Jackie M. Lafky, Joon H. Uhm, Caterina Giannini, Shaji K. Kumar, Teresa K. Kimlinger, Donald W. Northfelt, Patrick J. Flynn, Kurt A. Jaeckle, Timothy J. Kaufmann, Jan C. Buckner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4816–4823.
https://doi.org/10.1158/1078-0432.CCR-13-0708
Published: 02 September 2013
View article titled, Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Open the PDF for Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial in another window
Includes: Supplementary data